CVS Caremark®

|  |
| --- |
| Reference number(s) |
| 6239-A |

# Specialty Guideline Management Omvoh

## Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

| Brand Name | Generic Name |
| --- | --- |
| Omvoh | mirikizumab-mrkz |

## Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

### FDA-approved Indications1

* Treatment of moderately to severely active ulcerative colitis in adults
* Treatment of moderately to severely active Crohn’s disease in adults

All other indications are considered experimental/investigational and not medically necessary.

## Documentation

Submission of the following information is necessary to initiate the prior authorization review:

### Ulcerative colitis (UC) and Crohn’s disease (CD)

Continuation requests: Chart notes or medical record documentation supporting positive clinical response to therapy or remission.

## Prescriber Specialties

This medication must be prescribed by or in consultation with a gastroenterologist.

## Coverage Criteria

### Ulcerative colitis (UC)1,3,4,5

Authorization of 12 months may be granted for treatment of moderately to severely active ulcerative colitis.

### Crohn’s disease (CD)1,6,7

Authorization of 12 months may be granted for treatment of moderately to severely active Crohn’s disease.

## Continuation of Therapy

### Ulcerative colitis (UC)1,3,4,5

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain remission.

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active ulcerative colitis and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

* Stool frequency
* Rectal bleeding
* Urgency of defecation
* C-reactive protein (CRP)
* Fecal calprotectin (FC)
* Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
* Improvement on a disease activity scoring tool (e.g., Ulcerative Colitis Endoscopic Index of Severity [UCEIS], Mayo score)

### Crohn’s disease (CD)1,6,7

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active Crohn’s disease and who achieve or maintain remission.

Authorization of 12 months may be granted for all members (including new members) who are using the requested medication for moderately to severely active Crohn’s disease and who achieve or maintain a positive clinical response as evidenced by low disease activity or improvement in signs and symptoms of the condition when there is improvement in any of the following from baseline:

* Abdominal pain or tenderness
* Diarrhea
* Body weight
* Abdominal mass
* Hematocrit
* Appearance of the mucosa on endoscopy, computed tomography enterography (CTE), magnetic resonance enterography (MRE), or intestinal ultrasound
* Improvement on a disease activity scoring tool (e.g., Crohn’s Disease Activity Index [CDAI] score)

## Other1,2

For all indications: Member has had a documented negative tuberculosis (TB) test (which can include a tuberculosis skin test [TST] or an interferon-release assay [IGRA]) within 12 months of initiating therapy for persons who are naïve to biologic drugs or targeted synthetic drugs associated with an increased risk of TB.

If the screening testing for TB is positive, there must be further testing to confirm there is no active disease (e.g., chest x-ray). Do not administer the requested medication to members with active TB infection. If there is latent disease, TB treatment must be started before initiation of the requested medication.

Member cannot use the requested medication concomitantly with any other biologic drug or targeted synthetic drug for the same indication.

## Dosage and Administration

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

## References

1. Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2025.
2. Testing for TB Infection. Centers for Disease Control and Prevention. Retrieved on January 21, 2025 from: https://www.cdc.gov/tb/testing/index.html.
3. Talley NJ, Abreu MT, Achkar J, et al. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol. 2011;106(Suppl 1):S2-S25.
4. Rubin DT, Ananthakrishnan AN, Siegel CA, et al. 2019 ACG Clinical Guideline: Ulcerative Colitis in Adults. Am JGastroenterol*.* 2019;114:384-413.
5. Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical Practice Guidelines on the Management of Moderate to Severe Ulcerative Colitis. Gastroenterology*.* 2020;158:1450.
6. Lichtenstein GR, Loftus Jr EV, Isaacs KI, et al. ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018;113:481-517.
7. Feuerstein JD, Ho EY, Shmidt E, et al. AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn’s Disease. Gastroenterology. 2021;160:2496- 2508.